Evidence map›Paper›PMID 37742230›Full record

ArticleAging2023

Identification of senescence-related lncRNA prognostic index correlating with prognosis and radiosensitivity in prostate cancer patients.

Dechao Feng, Li Li, Xu Shi, Weizhen Zhu, Jie Wang, Ruicheng Wu, Dengxiong Li, Wuran Wei, Ping Han

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Dechao FengDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Li LiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Xu ShiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Weizhen ZhuDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Jie WangDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Ruicheng WuDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Dengxiong LiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Wuran WeiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Ping HanDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn increasing number of studies are shown how crucial a role cellular senescence plays in tumor development. In this study, we developed a senescence-related lncRNA prognostic index (SRLPI) to forecast radiosensitivity and the probability of biochemical recurrence (BCR) in patients with prostate cancer (PCa).

methodsPCa cohorts in TCGA and GEO databases were downloaded. Senescence-and prognosis-related lncRNA with differential expression in tumor and normal samples were identified and used to establish the SRLPI score. Mutation landscape, function pathway, tumor stemness and heterogeneity and tumor immune microenvironment were also analyzed. We performed the analysis using R 3.6.3 and the appropriate tools.

resultsA SRLPI score was constructed based on SNHG1 and MIAT in the TCGA cohort. Our classification of PCa patients into high- and low-risk groups was based on the median SRLPI score. When compared to the low-SRLPI group, the high-SRLPI group was more vulnerable to BCR (HR: 3.33). In terms of BCR-free survival and metastasis-free survival, the GSE116918 showed similar findings. Surprisingly, the SRLPI score demonstrated a high level of radiosensitivity for diagnosis (AUC: 0.98). Age, Gleason score, T stage, N stage, positive lymph nodes, and residual tumor were all significantly greater in patients with high SRLPI scores. Furthermore, this score was significantly related to markers of senescence. Protein secretion and androgen response were found to be substantially enriched in the low-SRLPI group, whereas E2F targets were found to be strongly enriched in the high-SRLPI group for pathway analysis. For the tumor microenvironment assessment, B cells, CD8+ T cells, immune score and TIDE score were positively related to SRLPI score while endothelial level was negatively associated with SRLPI score with statistical significance.

conclusionsWe developed a SRLPI score that was related to prognosis and radiosensitivity and might be helpful in clinical practice.

Indexed as

Cellular SenescenceProstatic NeoplasmsRadiation ToleranceRNA, Long NoncodingBiomarkers, TumorGene Expression Regulation, NeoplasticHumansMalePrognosisTumor MicroenvironmentBiomarkers, TumorRNA, Long Noncodingandrogen responsebiochemical recurrenceprostate cancerradiosensitivitysenescence-related lncRNA prognostic index

Identifiers

PMID37742230
PMCPMC10564441
OpenAlexW4386985064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.